Tenpoint Therapeutics, a Cambridge, UK-based biotechnology company pursuing vision-restoring engineered cell-based therapeutics and in vivo reprogramming, raised $70M in Series A funding.
Backers included British Patient Capital, F-Prime Capital, Sofinnova Partners, Qiming Venture Partners USA, Eight Roads and the UCL Technology Fund, among others.
The company intends to use the funds to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions.
Led by Eddy Anglade, MD and CEO, Tenpoint is a biotechnology company committed to advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases. Its regenerative medicine platform has potential to replace cells destroyed by both age-related and inherited ocular diseases.
Tenpoint was established based on the work of its scientific founders from Moorfields Eye Hospital, University College London Institute of Ophthalmology, Institut de la Vision in Paris and the University of Washington who have developed engineered cell-based therapeutics and performed translational research to establish proof-of-concept. Based on these foundational achievements, the company is advancing approaches to generate specialized ocular cell types both ex vivo and in vivo.
Tenpoint is led by renowned experts in both regenerative medicine and ophthalmology. As CEO, Eddy Anglade, MD brings decades of experience in clinical development in ophthalmic diseases with significant unmet needs. Vanessa King, PhD, Tenpoint’s founding CEO, led this financing of the company and will continue to support the organization as a strategic advisor. Tenpoint previously named ophthalmology innovator David Guyer, MD, to chair its board. Dr. Guyer currently serves as Chief Executive Officer of EyeBio and previously served as Executive Chairman of IVERIC bio, a company he co-founded under the name Ophthotech. As co-founder, CEO and director of Eyetech Pharmaceuticals, he oversaw the development and commercialization of Macugen® (pegaptanib sodium), the first anti-VEGF pharmacological treatment approved by the FDA for treatment of wet AMD.
FinSMEs
13/07/2023